Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATAI Life Sciences B.V.*

2.41
-0.0700-2.82%
Post-market: 2.430.0200+0.83%19:51 EDT
Volume:4.65M
Turnover:11.47M
Market Cap:483.81M
PE:-2.59
High:2.55
Open:2.55
Low:2.37
Close:2.48
Loading ...

Atai Life Sciences initiated with a Buy at Lucid Capital

TIPRANKS
·
06 Jun

ATAI Life Sciences and Beckley Psytech Merger: Strategic Moves and Promising Pipeline Justify Buy Rating

TIPRANKS
·
06 Jun

Strategic Merger and Financial Strength Propel ATAI Life Sciences to ‘Buy’ Rating

TIPRANKS
·
02 Jun

ATAI Life Sciences Announces Share Purchase Agreement

TIPRANKS
·
02 Jun

ATAI Life Sciences and Beckley Psytech Announce Definitive Agreement to Merge in Strategic All-Share Transaction

Reuters
·
02 Jun

Press Release: atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Dow Jones
·
02 Jun

ATAI Life Sciences NV Files Initial Statement of Beneficial Ownership for Director John Francis Hoffman

Reuters
·
24 May

ATAI Life Sciences Approves Key Governance Changes

TIPRANKS
·
22 May

ATAI Life Sciences NV Conducted Annual Shareholders Meeting

Reuters
·
22 May

TD Cowen Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)

TIPRANKS
·
21 May

ATAI Life Sciences: Promising Clinical Data and Strategic Investments Drive Buy Rating

TIPRANKS
·
21 May

Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug

MT Newswires Live
·
20 May

ATAI Life Sciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
20 May

Atai Life Sciences announces data from Part 2 of Phase 2a study of BPL-003

TIPRANKS
·
20 May

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

GlobeNewswire
·
20 May

ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones

TIPRANKS
·
20 May

ATAI Life Sciences: Strong Buy Rating Backed by Promising Trials and Robust Financial Health

TIPRANKS
·
19 May

ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts

TIPRANKS
·
18 May

Atai Life Sciences Reports First Quarter 2025 Financial Results

Reuters
·
14 May

ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M

Benzinga
·
14 May